Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Clinical Study of SyB D-0701 for Radiotherapy Induced Nausea and Vomiting

Trial Profile

Phase II Clinical Study of SyB D-0701 for Radiotherapy Induced Nausea and Vomiting

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Granisetron (Primary)
  • Indications Radiotherapy-induced nausea and vomiting
  • Focus Registrational; Therapeutic Use
  • Sponsors SymBio Pharmaceuticals
  • Most Recent Events

    • 29 Jan 2013 Primary endpoint 'Complete-control-of-nausea-and-vomiting' has not been met.
    • 01 Jan 2013 Status changed from active, no longer recruiting to completed.
    • 24 Oct 2012 Status changed from recruiting to active, no longer recruiting, as reported in a SymBio Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top